|
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS) Bundle
Explorez l'avenir financier de Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS) avec notre calculatrice DCF conviviale! Entrez vos hypothèses concernant la croissance, les marges et les coûts pour déterminer la valeur intrinsèque de Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS) et informer votre stratégie d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,892.2 | 3,267.9 | 2,778.5 | 3,075.4 | 2,009.5 | 1,879.1 | 1,757.2 | 1,643.1 | 1,536.5 | 1,436.8 |
| Revenue Growth, % | 0 | 12.99 | -14.98 | 10.69 | -34.66 | -6.49 | -6.49 | -6.49 | -6.49 | -6.49 |
| EBITDA | 1,272.8 | 1,678.1 | 1,948.8 | 1,556.9 | -46.1 | 803.6 | 751.5 | 702.7 | 657.1 | 614.5 |
| EBITDA, % | 44.01 | 51.35 | 70.14 | 50.63 | -2.29 | 42.77 | 42.77 | 42.77 | 42.77 | 42.77 |
| Depreciation | 154.5 | 139.6 | 164.4 | 185.9 | 205.0 | 119.4 | 111.7 | 104.4 | 97.7 | 91.3 |
| Depreciation, % | 5.34 | 4.27 | 5.92 | 6.04 | 10.2 | 6.36 | 6.36 | 6.36 | 6.36 | 6.36 |
| EBIT | 1,118.3 | 1,538.5 | 1,784.4 | 1,371.1 | -251.1 | 684.2 | 639.8 | 598.3 | 559.4 | 523.1 |
| EBIT, % | 38.67 | 47.08 | 64.22 | 44.58 | -12.5 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 |
| Total Cash | 743.7 | 902.0 | 846.5 | 1,159.7 | 642.0 | 576.7 | 539.3 | 504.3 | 471.5 | 440.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 589.3 | 658.6 | 476.5 | 878.5 | 569.5 | 430.6 | 402.7 | 376.6 | 352.1 | 329.3 |
| Account Receivables, % | 20.38 | 20.15 | 17.15 | 28.57 | 28.34 | 22.92 | 22.92 | 22.92 | 22.92 | 22.92 |
| Inventories | 537.6 | 537.9 | 653.9 | 705.3 | 736.3 | 444.1 | 415.3 | 388.3 | 363.1 | 339.5 |
| Inventories, % | 18.59 | 16.46 | 23.53 | 22.93 | 36.64 | 23.63 | 23.63 | 23.63 | 23.63 | 23.63 |
| Accounts Payable | 68.2 | 75.0 | 80.9 | 115.9 | 96.6 | 60.7 | 56.7 | 53.0 | 49.6 | 46.4 |
| Accounts Payable, % | 2.36 | 2.3 | 2.91 | 3.77 | 4.81 | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 |
| Capital Expenditure | -479.6 | -600.7 | -491.6 | -348.1 | -568.7 | -346.8 | -324.3 | -303.3 | -283.6 | -265.2 |
| Capital Expenditure, % | -16.58 | -18.38 | -17.69 | -11.32 | -28.3 | -18.46 | -18.46 | -18.46 | -18.46 | -18.46 |
| Tax Rate, % | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 | 70.28 |
| EBITAT | 938.5 | 1,311.7 | 1,542.8 | 1,172.3 | -74.6 | 507.5 | 474.5 | 443.8 | 415.0 | 388.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -445.3 | 787.8 | 1,287.6 | 591.6 | -179.5 | 675.2 | 314.8 | 294.3 | 275.2 | 257.4 |
| WACC, % | 6.5 | 6.51 | 6.51 | 6.51 | 6.43 | 6.49 | 6.49 | 6.49 | 6.49 | 6.49 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,557.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 263 | |||||||||
| Terminal Value | 5,844 | |||||||||
| Present Terminal Value | 4,267 | |||||||||
| Enterprise Value | 5,825 | |||||||||
| Net Debt | 110 | |||||||||
| Equity Value | 5,715 | |||||||||
| Diluted Shares Outstanding, MM | 2,136 | |||||||||
| Equity Value Per Share | 2.68 |
What You Will Receive
- Authentic (600867SS) Financial Data: Pre-loaded with Tonghua Dongbao’s historical and forecasted financial information for accurate analysis.
- Fully Customizable Template: Easily adjust key variables such as revenue growth, WACC, and EBITDA margins.
- Instant Updates: Watch the intrinsic value of Tonghua Dongbao update in real-time based on your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for reliable DCF outcomes.
- Intuitive Design: Enjoy a straightforward layout and clear guidance suitable for all skill levels.
Key Features
- Comprehensive DCF Calculator: Houses in-depth unlevered and levered DCF valuation models tailored for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable variables specific to the pharmaceutical industry.
- Customizable Forecast Assumptions: Easily adjust growth rates, capital expenditures, and discount rates for precise projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Functions
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS) (historical and forecasted).
- Step 3: Modify key assumptions (highlighted in yellow) based on your insights.
- Step 4: Observe automatic recalculations for the intrinsic value of Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS).
- Step 5: Utilize the results for investment strategies or reporting purposes.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Financial Data: Historical and projected financials for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS) are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly Interface: Step-by-step guidance to navigate the process smoothly.
Who Should Benefit from This Product?
- Investors: Accurately assess the fair value of Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS) prior to making investment choices.
- CFOs: Utilize a sophisticated DCF model for enhanced financial reporting and analysis.
- Consultants: Quickly customize the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Employ it as a teaching resource to illustrate various valuation methodologies.
What the Template Includes
- Historical Data: Features past financial performance and baseline forecasts for Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS).
- DCF and Levered DCF Models: Comprehensive templates for calculating the intrinsic value of Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS).
- WACC Sheet: Pre-configured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize key drivers such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: An exhaustive analysis of Tonghua Dongbao Pharmaceutical Co., Ltd. (600867SS)'s financials.
- Interactive Dashboard: Dynamically visualize valuation results and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.